AR105755A1 - Compuestos que participan en unión cooperativa y sus usos - Google Patents
Compuestos que participan en unión cooperativa y sus usosInfo
- Publication number
- AR105755A1 AR105755A1 ARP160100047A ARP160100047A AR105755A1 AR 105755 A1 AR105755 A1 AR 105755A1 AR P160100047 A ARP160100047 A AR P160100047A AR P160100047 A ARP160100047 A AR P160100047A AR 105755 A1 AR105755 A1 AR 105755A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- target
- compounds
- presenter
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101925P | 2015-01-09 | 2015-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105755A1 true AR105755A1 (es) | 2017-11-08 |
Family
ID=56356469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100047A AR105755A1 (es) | 2015-01-09 | 2016-01-08 | Compuestos que participan en unión cooperativa y sus usos |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10039839B2 (enExample) |
| EP (3) | EP3757109A1 (enExample) |
| JP (4) | JP2018507251A (enExample) |
| AR (1) | AR105755A1 (enExample) |
| MA (1) | MA41381A (enExample) |
| TW (1) | TW201629069A (enExample) |
| WO (1) | WO2016112279A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| EP3355930A4 (en) | 2015-10-01 | 2019-03-06 | Warp Drive Bio, Inc. | METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES |
| EP4085933A3 (en) | 2016-04-12 | 2023-01-11 | Ginkgo Bioworks, Inc. | Compositions and methods for the production of compounds |
| CN110785428A (zh) * | 2017-04-05 | 2020-02-11 | 锐新医药公司 | 用于分析蛋白质-蛋白质界面的方法和试剂 |
| KR20240033100A (ko) * | 2017-04-05 | 2024-03-12 | 레볼루션 메디슨즈, 인크. | 협동 결합에 참여하는 화합물 및 그의 용도 |
| WO2018195134A1 (en) * | 2017-04-18 | 2018-10-25 | X-Chem, Inc. | Methods for identifying compounds |
| AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN116083290B (zh) * | 2022-11-21 | 2024-06-14 | 陕西省微生物研究所 | 一种铅锌和/或抗生素和/或抗性基因污染土壤修复的复合微生物菌剂及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2089723T3 (es) | 1992-03-27 | 1996-10-01 | American Home Prod | 29-demetoxirapamicina para inducir la inmunodepresion. |
| DK0725778T3 (da) | 1993-09-20 | 2001-12-17 | Univ Leland Stanford Junior | Rekombinant produktion af hidtil ukendte polyketider |
| IL112873A (en) | 1994-03-08 | 2005-03-20 | Wyeth Corp | Rapamycin-fkbp12 binding proteins, their isolation and their use |
| GB9410142D0 (en) | 1994-05-20 | 1994-07-06 | Univ Warwick | Carbapenems |
| GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US6902913B2 (en) | 1997-04-30 | 2005-06-07 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
| US6153383A (en) | 1997-12-09 | 2000-11-28 | Verdine; Gregory L. | Synthetic transcriptional modulators and uses thereof |
| ATE473759T1 (de) * | 1998-05-22 | 2010-07-15 | Univ Leland Stanford Junior | Bifunktionelle moleküle sowie darauf basierende therapien. |
| GB9927191D0 (en) | 1999-11-17 | 2000-01-12 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| US20070203168A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
| WO2010031185A1 (en) | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| US8962329B2 (en) | 2008-09-24 | 2015-02-24 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Gene cluster |
| WO2010088573A1 (en) | 2009-01-30 | 2010-08-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c infection |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| WO2011009938A2 (en) | 2009-07-24 | 2011-01-27 | Universite Henri Poincare Nancy 1 | Stambomycin and derivatives, their production and their use as drugs |
| AU2010298338A1 (en) | 2009-09-22 | 2012-04-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP2492344B1 (en) | 2009-10-22 | 2016-04-06 | PeptiDream Inc. | Rapid display method in translational synthesis of peptide |
| EP2646440A4 (en) | 2010-11-30 | 2014-06-18 | Univ Johns Hopkins | CYCLIC HYBRID LIBRARIES AND SCREENS FOR THIS |
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| WO2012174489A2 (en) | 2011-06-15 | 2012-12-20 | The Ohio State University | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| EP2806274A1 (en) | 2013-05-24 | 2014-11-26 | AIT Austrian Institute of Technology GmbH | Lung cancer diagnostic method and means |
| CN106255882A (zh) | 2014-03-03 | 2016-12-21 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于检测铜绿假单胞菌的方法和装置 |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| MX2021007468A (es) * | 2018-12-21 | 2021-08-05 | Revolution Medicines Inc | Compuestos que participan en la union cooperativa y usos de los mismos. |
-
2016
- 2016-01-05 TW TW105100137A patent/TW201629069A/zh unknown
- 2016-01-07 MA MA041381A patent/MA41381A/fr unknown
- 2016-01-08 EP EP20176025.3A patent/EP3757109A1/en not_active Withdrawn
- 2016-01-08 US US14/991,403 patent/US10039839B2/en active Active
- 2016-01-08 JP JP2017555427A patent/JP2018507251A/ja active Pending
- 2016-01-08 AR ARP160100047A patent/AR105755A1/es unknown
- 2016-01-08 EP EP24222224.8A patent/EP4545521A3/en active Pending
- 2016-01-08 EP EP16735470.3A patent/EP3247377A4/en not_active Withdrawn
- 2016-01-08 WO PCT/US2016/012631 patent/WO2016112279A1/en not_active Ceased
-
2018
- 2018-07-16 US US16/036,141 patent/US20180318434A1/en not_active Abandoned
-
2019
- 2019-11-25 JP JP2019211918A patent/JP2020063256A/ja active Pending
-
2021
- 2021-06-10 US US17/344,566 patent/US20220143202A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076767A patent/JP2022093718A/ja active Pending
-
2024
- 2024-08-02 JP JP2024127925A patent/JP2024149655A/ja active Pending
- 2024-09-27 US US18/899,370 patent/US20250121077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018507251A (ja) | 2018-03-15 |
| EP3757109A1 (en) | 2020-12-30 |
| TW201629069A (zh) | 2016-08-16 |
| EP3247377A1 (en) | 2017-11-29 |
| WO2016112279A8 (en) | 2016-09-29 |
| US20220143202A1 (en) | 2022-05-12 |
| US10039839B2 (en) | 2018-08-07 |
| JP2024149655A (ja) | 2024-10-18 |
| MA41381A (fr) | 2017-11-28 |
| US20180318434A1 (en) | 2018-11-08 |
| US20160199506A1 (en) | 2016-07-14 |
| US20250121077A1 (en) | 2025-04-17 |
| JP2020063256A (ja) | 2020-04-23 |
| EP3247377A4 (en) | 2018-06-13 |
| JP2022093718A (ja) | 2022-06-23 |
| EP4545521A2 (en) | 2025-04-30 |
| EP4545521A3 (en) | 2025-08-06 |
| WO2016112279A1 (en) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105755A1 (es) | Compuestos que participan en unión cooperativa y sus usos | |
| EP4289950A3 (en) | Macrocyclic compounds that participate in cooperative binding and medical uses thereof | |
| CL2021003457A1 (es) | Proteínas de fusión flt3l-fc y métodos de uso | |
| AU2018256548A1 (en) | Activation of bioluminescence by structural complementation | |
| EP4242304A3 (en) | Methods and reagents for analyzing protein-protein interfaces | |
| BR112018006811A2 (pt) | compostos terapêuticos e métodos | |
| CO2021003724A2 (es) | Proteínas de fijación a sirpα y métodos de uso de estas | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| BR112018006237A2 (pt) | proteínas de ligação a pd-1 e métodos de uso das mesmas | |
| WO2020236972A3 (en) | Non-classi engineered crispr-cas polynucleotide targeting system | |
| BR112017018941A8 (pt) | Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20 | |
| EP4365597A3 (en) | Methods of assaying proteins | |
| MX392031B (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2 | |
| CL2019000119A1 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123. | |
| EA201891619A1 (ru) | Химерные белки и способы регулирования экспрессии генов | |
| CO2018013104A2 (es) | Polipéptidos de fusión cd40l-fc y sus métodos de uso | |
| AU2017266905A1 (en) | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof | |
| MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
| EP4517318A3 (en) | Optical system for capillary electrophoresis | |
| MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
| WO2020154714A3 (en) | Systems and methods for modulating crispr activity | |
| EP4001310A3 (en) | Ion channel modulators and uses thereof | |
| EA202090335A1 (ru) | Взаимоусиливающие комбинации гербицидов | |
| EP4306544A3 (en) | Production of heteromultimeric proteins using mammalian cells | |
| BR112019010034A2 (pt) | fator viii alvejado de hemácia e método de uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |